

Information regarding proposed Board of Directors

Thomas von Koch



Proposed for re-election as Board Member and re-election as Chairman of the Board.

Year of birth	1966
Education/Experience	M.Sc. in Financial Economics and Accounting & Finance, Stockholm School of Economics, Sweden, 1988-1992
Position in the Company	Co-founder of Bactiguard and CEO 2023-2024. Chairman of the Board 2005–2015, 2019–2023, 2024–.
Other significant positions	Previously partner and CEO (2014-2018) of private equity firm EQT. Special advisor to EQT. Investor, owner and Board Member of A3P, Smartcella Holding AB, and TomEnterprise AB.
Holdings of securities in the company	Class A shares: 2 000 000 (through legal entity). Class B shares: 7 501 513 (through a company controlled by Thomas von Koch as the beneficiary)
Independence	Not independent in relation to the Company, its management or its major shareholders
Year elected to the Board of Directors	2005 and 2019

Professor Anna Martling



Proposed for re-election as Board Member

Year of birth	1969
Education/Experience	<p>MD, Ph.D, Karolinska Institutet, Full Professor, Karolinska Institutet (since 2014). Senior Consultant Surgeon, Karolinska University Hospital (since 2010).</p> <p>Former Head of Department of Surgery, Karolinska Hospital (2006-2008), Deputy Head of Center of Gastrointestinal Disease, Karolinska University Hospital (2010-2013), Dean, Campus North Karolinska Institutet (2019-2023), Scientific Director Life Science, Karolinska Institutet (2024)</p>
Position in the Company	Board member and member of the audit committee.
Other significant positions	Board Member of Radiumhemmets Forskningsfonder, Forska!Sverige, European Society of Coloproctology (ESCP), Sophiahemmet and Smartcella.
Holdings of securities in the company	3,575 B-shares as personal holdings and 28,818 call options.
Independence	Independent in relation to the Company, the management and the Company's major shareholders.
Year elected to the Board of Directors	2019

Magdalena Persson



Proposed for re-election as Board Member

Year of birth

1971

Education/Experience

Master's degree in international economics and licentiate degree in industrial economics from Linköping University.

Former CEO of Interflora and SamSari, as well as several roles within Microsoft and WM Data. Chairperson of the Board of Affecto Plc, Nexon Asia Pacific and Iver Holding AB. Board member of NCAB Group.

Position in the Company

Board member and member of the remuneration committee

Other significant positions

Chairperson of the Board of SK Shieldus (South Korea) and Universidad Europea. Board member Qarbo AB, as well as advisor to private equity firm EQT.

Holdings of securities in the company

28,818 call options

Independence

Independent in relation to the Company, the management and the Company's major shareholders.

Year elected to the Board of Directors

2022

Jan Ståhlberg



Proposed for re-election as Board Member

Year of birth

1962

Education/Experience

BSc Business and Economics, Stockholm School of Economics. Studies at the MBA program at New York University, Stern School of Business.

Partner, Deputy CEO and Deputy Chairman of private equity firm EQT.

Position in the Company

Board member, member of the remuneration committee and chairman of the audit committee.

Other significant positions

Board Member of Trelleborg AB and ITB-Med AB. Founder and CEO of Trill Impact AB.

Holdings of securities in the company

3,605,150 B shares as personal holdings

Independence

Independent in relation to the Company and management. Not independent in relation to the Company's major shareholders.

Year elected to the Board of Directors

2018

Dr Richard Kuntz



Proposed for re-election as a Board Member.

Year of birth

1957

Education/Experience

BA Miami University, MD Case Western Reserve University School of Medicine, MSc in Biostatistics Harvard T.H. Chan School of Public Health, Harvard University. Residency/chief residency internal medicine at University of Texas Southwestern Medical School, Parkland Hospital. Fellowships cardiovascular diseases and interventional cardiology at Harvard Medical School, Beth Israel Hospital.

Previous CMO/CSO Medtronic PLC. Founder/CSO of Harvard Clinical Research Institute, Boston. Assoc. Professor of Medicine Harvard Medical School, Chief of Division of Clinical Biometrics, and Interventional Cardiologist of cardiovascular diseases division at Brigham and Women's Hospital, Boston.

Position in the Company

Board member

Other significant positions

Board Member of Diamedica Therapeutics Inc., Identiv Inc., Cognito Therapeutics, Inc., Ripple Medical, Elucid, and CorFlow.

Holdings of securities in the company

121,655 call options

Independence

Independent in relation to the Company, the management and the Company's major shareholders.

Year elected to the Board of Directors

2023

This is a translation of the Swedish version. In the event of deviations, the Swedish version available on the company's website applies, <https://ir.bactiguard.com/>.

This document was last updated on: 13 April 2026